

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

INSIDE INFORMATION UPDATE ON INVESTIGATION AGAINST DIRECTORS AND CONTROLLING SHAREHOLDERS

This announcement is made by Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rules 13.09(2), 13.51(2) and 13.51B(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated May 12, 2026, May 13, 2026 and September 11, 2026 in relation to suspected violations of laws and regulations regarding information disclosure related to changes in the Company’s shareholding in A shares by Mr. Ye Xiaoping (“**Mr. Ye**”), and Ms. Cao Xiaochun (“**Ms. Cao**”), directors and controlling shareholders of the Company.

The Company is notified that on October 16, 2026, Mr. Ye and Ms. Cao received the Decision of Administrative Penalty (《行政處罰決定書》) (2026) No. 38 (the “**Decision**”) from the Zhejiang Regulatory Bureau (the “**Zhejiang Regulatory Bureau**”) of the China Securities Regulatory Commission (the “**CSRC**”).

The main contents of the Decision are as follows:

In accordance with the relevant requirements in the Securities Law of the People's Republic of China as amended in 2019 (the "**Securities Law**"), the Zhejiang Regulatory Bureau had initiated investigation proceedings in respect of the controlling shareholders of the Company and its persons acting in concert, and lawfully notified the parties of the facts, reasons, justifications and legitimate rights enjoyed by the parties in accordance with the relevant laws. The parties have not submitted any statement or defence nor requested a hearing. The investigation and handling of the case have now been concluded.

Upon investigation, the parties have been found to have committed the following illegal acts:

On September 20, 2019, the aggregate proportion of voting shares issued by the Company held by Mr. Ye and Ms. Cao reached a cumulative change of 5%. Mr. Ye and Ms. Cao failed to timely disclose the Simplified Report on Changes in Equity Interests (《簡式權益變動報告書》) and only made supplementary disclosures on May 12, 2026.

The aforesaid illegal facts were sufficiently established by evidence including listed company announcements, inquiry transcripts of relevant persons, written statements, securities account records and other materials.

The aforesaid conduct of Mr. Ye and Ms. Cao were in violation of paragraph 2 of article 86 of the Securities Law of the People's Republic of China (as amended in 2005) (the "**2005 Securities Law**") and paragraph 2 of article 63 of the Securities Law, and constitute information disclosure violations as specified in paragraph 2 of article 193 of the 2005 Securities Law and paragraph 1 of article 197 of the Securities Law.

Based on the facts, nature, circumstances and degree of social harm of the parties' illegal acts, and pursuant to paragraph 1 of article 197 of the Securities Law, the Zhejiang Regulatory Bureau have decided to impose a warning and a fine of RMB500,000 to each of Mr. Ye and Ms. Cao.

The aforesaid parties shall remit the fine directly to the national treasury within 15 days upon receipt of the Decision and file a copy of the payment proof marked with the names of the parties to the Zhejiang Regulatory Bureau. If any party are aggrieved at the Decision, he/she may apply to the CSRC for administrative review within 60 days upon receipt of the Decision or initiate administrative proceedings directly at a people's court with jurisdiction within 6 months from the receipt of the Decision. The Decision will not be suspended during review or proceedings.

On the same day, the Shenzhen Stock Exchange (“SZSE”) also issued a disciplinary determination of public criticism against Mr. Ye and Ms. Cao (Shen Zheng Shang (2026) No. 1389 (the “**Determination**”)). Pursuant to the Determination, the illegal acts committed by Mr. Ye and Ms. Cao were in violation of the relevant provisions of Article 1.4, paragraph 1 of Article 2.3.1, paragraph 1 of Article 2.3.10 and Article 5.1.1 of the ChiNext Market Listing Rules (Revised in December 2020) of SZSE. In view of the aforesaid violation facts and circumstances, pursuant to Article 12.5 of the ChiNext Market Listing Rules (Revised in December 2020) of SZSE, upon review and approval by the SZSE Self-Regulatory Supervision and Disciplinary Sanctions Committee, the SZSE has made the following disciplinary decision:

to impose a sanction of public criticism against Mr. Ye and Ms. Cao; and

the aforesaid illegal acts of Mr. Ye and Ms. Cao and the sanction imposed by the SZSE will be recorded in the securities and futures market integrity archive database by the SZSE.

For further details in respect of the Decision and the Determination, please refer to the overseas regulatory announcement of the Company dated October 16, 2026.

The board of directors of the Company are of the view that the Decision and the Determination relate to information disclosure matters arising from historical changes in shareholdings in A shares of the Company, and such shareholding changes have already been disclosed subsequently in the Company’s announcements and periodic reports. Such matters are unrelated to the Company’s operations and will not affect the Group’s normal operations. Further announcement(s) will be made to keep the shareholders of the Company and the public informed of the development in this matter in due course.

The shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, October 16, 2026

As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu; the employee Director is Mr. Wu Hao; the independent non-executive Directors are Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Siu Paul Yu Hay.